-
公开(公告)号：US20160168223A1
公开(公告)日：2016-06-16
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
IPC: C07K14/50
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
公开(公告)号：US20140213512A1
公开(公告)日：2014-07-31
申请号：US14241848
申请日：2012-08-30
Applicant: Amgen Inc.
Inventor： Murielle Marie Ellison , Shanaka Stanislaus , Jing Xu
IPC: A61K38/18
CPC classification number: A61K38/1825
Abstract: Methods of treating metabolic diseases and disorders using a FGF21 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 1 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels, diabetic nephropathy, neuropathy, retinopathy, ischemic heart disease, peripheral vascular disease and cerebrovascular disease
Abstract translation: 提供了使用FGF21多肽治疗代谢疾病和病症的方法。 在各种实施方案中，代谢疾病或病症是1型糖尿病，肥胖症，血脂异常，葡萄糖水平升高，胰岛素水平升高，糖尿病性肾病，神经病变，视网膜病变，缺血性心脏病，外周血管疾病和脑血管疾病
-
公开(公告)号：US20250136653A1
公开(公告)日：2025-05-01
申请号：US18737435
申请日：2024-06-07
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
Patent Agency Ranking
公开(公告)号：US10905772B2
公开(公告)日：2021-02-02
申请号：US15872841
申请日：2018-01-16
Applicant: AMGEN INC.
Inventor： Yuan Cheng , Chawita Netirojjanakul , Jerry Ryan Holder , Bin Wu , James R. Falsey , Bradley J. Herberich , Kelvin Sham , Leslie P. Miranda , Shu-Chen Lu , Murielle M. Veniant-Ellison , Shanaka Stanislaus , Junming Yie , Jing Xu
IPC: A61K47/68 , A61K38/26 , A61P3/10 , C07K16/28 , A61K39/395
Abstract: Methods of treating metabolic diseases and disorders using a composition comprising an antigen binding protein specific for the GIPR polypeptide conjugated to a GLP-1 receptor agonist are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises an antibody or functional fragment thereof comprising a cysteine at one or more conjugation site(s) wherein the GLP-1 receptor agonist is conjugated to the antibody or functional fragment thereof through the side-chain of the cysteine residue.
-
公开(公告)号：US09273106B2
公开(公告)日：2016-03-01
申请号：US14134482
申请日：2013-12-19
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides FGF21 mutant polypeptides with reduced proteolysis and aggregation, pharmaceutical compositions comprising the same.
Abstract translation: 本发明提供具有降低的蛋白水解和聚集的FGF21突变体多肽，其包含其的药物组合物。
-
公开(公告)号：US20190023757A1
公开(公告)日：2019-01-24
申请号：US15996232
申请日：2018-06-01
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US10011642B2
公开(公告)日：2018-07-03
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
-
18.发明授权公开(公告)号：US09493530B2
公开(公告)日：2016-11-15
申请号：US14167662
申请日：2014-01-29
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。 在一些实施方案中，FGF21突变体多肽包含位置98,171和/或180处的取代。
-
-
-
-
-
-
-
Search Results
18
records
(took 0.01 seconds)
